Active, not recruitingPhase 3NCT04923893

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Studying Infantile neuroaxonal dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Janssen Research & Development, LLC
Principal Investigator
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Intervention
Bortezomib(drug)
Enrollment
743 target
Eligibility
18 years · All sexes
Timeline
20212036

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04923893 on ClinicalTrials.gov

Other trials for Infantile neuroaxonal dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Infantile neuroaxonal dystrophy

← Back to all trials